AIM ImmunoTech Announces First Subject Dosed in the Netherla

14.02.2024 - Phase 1b portion of the study expected to be completed within six monthsOCALA, Fla., Feb. 14, 2024 (GLOBE NEWSWIRE) - AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced the first subject has been dosed at Erasmus ...

Related Keywords

Jenene Thomas , Twitter , Exchange Commission , Facebook , Linkedin , Immunotech Inc , Pancreato Biliary Surgeon , Response Evaluation , Private Securities Litigation Reform Act , Investor Contact , Aim Immunotech Chart , Im Immunotech Kurs , Im Immunotech Aktie ,